JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2017, Vol. 55 ›› Issue (7): 38-42.doi: 10.6040/j.issn.1671-7554.0.2016.856

Previous Articles     Next Articles

Preliminary study of tissue distribution and safety of HSV-2 DNA vaccine in mice

JIAO Fengping1, ZHANG Haitao2, ZHAO Yinghui1, TIAN Zhaoju1, YANG Shulin1   

  1. 1. Department of Clinical Microbiology, School of Public Health, Taishan Medical University, Taian 271016, Shangdong, China;
    2. Department of Neonatology, Maternal and Child Care Service Centre, Taian 271016, Shangdong, China
  • Received:2016-07-15 Online:2017-07-10 Published:2017-07-10

PDF (PC)

252

Abstract: Objective To investigate preliminarily the tissue distribution and safety of HSV-2 DNA vaccine pc-P6-gBCTL-TBK-1 in mice. Methods The recombinant plasmid pc-P6-gBCTL-TBK-1 was injected into BALB/c mice with 100 μg per mouse for three times at every other week. Heart, liver, spleen, kidney, lung, brain, blood and muscle tissues of immune mice were collected at 24 h, 7 d, 21 d, 35 d and 49 d after inoculation, then total DNAs of tissues were extracted, and the tissue distribution of plasmid DNA and the possibility of integration with host genome were detected by PCR assay. Results At 24 h, 7 d, 21 d and 35 d after the last immunization, the plasmid DNA was detected in heart, liver, spleen, kidney, lung, brain and muscle tissues. At 49 d after the last immunization, the plasmid DNA was detected only in muscle tissue. The gel-purified genomic DNA was detected negative by PCR assay. Conclusion The plasmid pc-P6-gBCTL-TBK-1 can spread quickly to the heart, liver, spleen, kidney, lung, brain, blood and muscle tissues of the mice. With the extention of time, the plasmid DNA only distributes in muscle tissue of vaccination, and the DNA does not integrate with the host genome, which suggests that the plasmid is safe.

Key words: Herpes simplex virus type 2, Tissue distribution, Safety, DNA vaccine

CLC Number: 

  • R373.11
[1] 孙树汉. 核酸疫苗[M].上海:上海第二军医大学出版社, 2000:158-160.
[2] Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women:systematic review and meta-analysis of longitudinal studies[J]. AIDS, 2006, 20(1):73-83.
[3] Önnheim K, Ekblad M, Görander S, et al. Vaccination with the secreted glycoprotein G of herpes simplex virus 2 induces protective immunity after genital infection[J]. Viruses, 2016, 8(4):110.
[4] Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines:current progress[J]. Clin Infect Dis, 2011, 53(3):296-302.
[5] Ingolotti M, Kawalekar O, Shedlock DJ, et al. DNA vaccines for targeting bacterial infections[J]. Expert Rev Vaccines, 2010, 9(7):747-763.
[6] Liu MA. DNA vaccines:an historical perspective and view to the future[J]. Immunol Rev, 2011, 239(1):62-84.
[7] Yu X, Wang Y, Xia Y, et al. A DNA vaccine encoding VP22 of herpes simplex virus type I(HSV-1)and OprF confers enhanced protection from Pseudomonas aeruginosa in mice[J]. Vaccine, 2016, 34(37):4399-4405.
[8] Cova L. Present and future DNA vaccines for chronic hepatitis B treatment[J]. Expert Opin Biol Ther, 2016. [Epub ahead of print]
[9] Song X, Zhao X, Xu L, et al. Immune protection duration and efficacy stability of DNA vaccine encoding Eimeria tenella TA4 and chicken IL-2 against coccidiosis[J]. Res Vet Sci, 2016, 25(111):31-35.
[10] 邱春红,陈开廷,王永堂,等.核酸疫苗的安全性及其优化策略研究[J].生命科学, 2013, 25(9):857-863. QIU Chunhong, CHEN Kaiting, WANG Yongtang, et al. The research on safety of DNA vaccine and its optimization[J]. Chinese Bulletin of Life Sciences, 2013, 25(9):857-863.
[11] 焦凤萍,王玉,于爱莲,等.重组质粒pcDNA3.1(-)-P6-gBCTL-TBK-1的免疫效果评价[J]. 山东大学学报(医学版), 2017, 55(3): 75-78. JIAO Fengping, WANG Yu, YU Ailian, et al. Immunogenicity of the eukaryotic expression vector pcDNA3.1(-)-P6-gBCTL-TBK-1[J]. Journal of Shandong University(Health Sciences), 2017, 55(3): 75-78.
[12] Gong P, Gao L, Guo Y, et al. Toxoplasma gondii: protective immunity induced by a DNA vaccine expressing GRA1 and MIC3 against toxoplasmosis in BALB/c mice[J]. Exp Parasitl, 2016, 6(16):131-136.
[13] Valenta R, Campana R, Focke-Tejkl M, et al. Vaccine development for allergen specific immunotherapy based on recombinant allergens and synthetic allergen peptides:Lessons from the past and novel mechanisms of action for the future[J]. J Allergy Clin Immunol, 2016, 137(2):351- 357.
[14] 徐颖之,郑海发.单纯疱疹病毒2型疫苗的研究进展[J].中国生物制品学杂志, 2016, 29(9):997-1003. XU Yingzhi, ZHENG Haifa. Progress in research on vaccine against herpes simplex virus type 2[J]. Chin J Biologicals September, 2016, 29(9):997-1003.
[15] 周晓波,朱明.一种鸡球虫疫苗的生物安全性评价[J].甘肃畜牧兽医, 2015, 45(1):45-48.
[16] 杨海燕,陈光明,崔一民,等.电脉冲介导的治疗性双质粒HBV DNA疫苗的临床安全性及免疫原性研究[J]. 解放军医学杂志, 2013, 38(3):204-209. YANG Haiyan, CHEN Guangming, CUI Yimin, et al. Clinical study on safety and immunogenicity of therapeutic dual-plasmid HBV DNA vaccine mediated by in vivo electroporation [J]. Med J Chin PLA, 2013, 38(3):204-209.
[17] 刘欣,梁爱心,刘兴斌,等.生长抑素DNA 疫苗表达产物在小鼠组织细胞中的分布[J].黑龙江畜牧兽医, 2013, 11(6):26-30. LIU Xin, LIANG Aixin, LIU Xingbin, et al. Distribution of expression products of somatostatin DNA vaccine in the tissues and cells of mice [J]. Heilongjiang Animal Science and Veterinary Medicine, 2013, 11(6):26-30.
[18] 杨海,王芳宇. DNA疫苗的研究进展[J].中国畜牧兽医, 2013, 14(1):72-76.
[19] 蔡胜蓝,向选东,汪世平,等.日本血吸虫编码基因pcDNA3/SJHGPRT核酸疫苗在免疫宿主体内分布的观察[J].中国血吸虫病防治杂志, 2009, 21(3):174-178. CAI Shenglan, XIANG Xuandong, WANG Shiping, et al. Distribution of moded gene DNA vaccine pcDNA3/SJHGPRT against schistosoma japonicum in immune-mice[J]. Chin J Schisto Control, 2009, 21(3):174-178.
[20] 古小彬,郝桂英,谢跃,等.疥螨副肌球蛋白DNA疫苗在小鼠体内的分布和安全性分析[J]. 中国兽医科学, 2012, 42(9):927-931. GU Xianbin, HAO Guiying, XIE Yue, et al. Tissue distribution and safety of Sarcoptes scabiei paramyosin DNA vaccine in mice [J]. Chinese Veterinary Science, 2012, 42(9):927-931.
[21] 周凤娟,孙树汉.乙肝表面抗原核酸疫苗的构建及其与宿主染色体整合的可能性分析[J].第二军医大学学报, 2002, 23(8):816-818. ZHOU Fengjuan, SUN Shuhan. Construction of hepatitis B S antigen DNA vaccine and its potential integration into host cell genome [J]. Academic Journal of Second Military Medical University, 2002, 23(8):816-818.
[22] 殷俊磊,朱时杰,周碧君,等.山羊痘DNA疫苗pVAX1-P32的构建及其安全性评估[J].中国兽医科学, 2010, 40(10):1052-1056. YIN Junlei, ZHU Shijie, ZHOU Bijun, et al. Construction and safety evaluation of the DNA vaccine pVAX1-P32 against goat pox[J]. Chinese Veterinary Science, 2010, 40(10):1052-1056.
[23] Saha R, Killian S, Donofrio RS. DNA vaccines:a mini review [J]. Recent Pat DNA Gene Seq, 2011, 5(2):92-96.
[24] Arce FM, Rios CM, Carrillo SC, et al. Prophylactic and therapeutic DNA vaccines against Chagas disease[J]. Parasit Vectors, 2015, 24(8):121.
[25] Myhr AI. DNA vaccines:regulatory considerations and safety aspects[J]. Curr Issues Mol Biol, 2016, 5(22):79-88.
[1] JIAO Fengping, WANG Yu, YU Ailian, TIAN Zhaoju, YANG Shulin. Immunogenicity of the eukaryotic expression vector pcDNA3.1(-)-P6-gBCTL-TBK-1 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 75-78.
[2] LIU Songtao, SHEN Bin, LIN Hui, LI Xiangwei, WEN Zhaoke. A comparative study of total thoracoscopic mitral valve replacement under heart beating and heart arrest [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 39-43.
[3] XU Chuang, QI Dachun, LI Xianrang, ZU Meng, LI Jian, LIU Mingting. Do we really need wound drainage in hip arthroplasty? A meta-analysis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(6): 43-49.
[4] WANG Lin, LÜ Gang, HAN Yali, GUO Jingjing, ZHAO Qunli, HE Shenyi. Construction of an eukaryotic vector of rhoptry protein 7 from Toxoplasma gondii and its immunoprotective effect [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 11-15.
[5] HOU Xin-guo， ZHOU Ke-hua, ZHEN Xiao-hui, SONG Jun, ZHANG Liang, JIAO Lei， CHEN Li . Efficacy and safety of recombinant human glucagonlike peptide-1 in combination with metformin in patients with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 1-.
[6] SHENG Mei-yan1，2，LIU Ming-tao1，3，ZHANG Yun1， 3，WEN Kun2, WANG Ben-jie4, LI Yu1. Pharmacokinetics of levofloxacin in rabbit blood and tissue fluid after intravenons injection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(8): 47-.
[7] . Prediction of HBV multiepitope vaccines based on GIS in the population of China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(7): 125-132.
[8] ZHANG Xiao-Li, LI Xiao, WANG Xin, ZHENG Lin, DIAO Wei-Meng, JI Mei. null [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(12): 17-20.
[9] . Valuation of theoretical immune response status of HBV multiepitope 
vaccines in existence in the population of China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(10): 114-117.
[10] GAO Yan-hui,LI Bao-iu,GAN Yi-u,DONG Xin,CHENG Xiu-min,ZHAO Yan-biao. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(8): 823-826.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd